|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
102-103
|
|
pubmed:dateCreated |
2011-3-17
|
|
pubmed:abstractText |
For treating Helicobacter pylori infection, it is still debatable whether proton pump inhibitor can be replaced by H2-receptor antagonist without compromising efficacy. Lafutidine is a newly synthesized H2-receptor antagonist and has been shown to exhibit antisecretory action. This meta-analysis investigated the efficacy of lafutidine-based triple therapy for Helicobacter pylori infection. METHODOGY: We searched PUBMED; EMBASE, the Cochrane Library and Chinese Biomedical Database databases to identify randomized controlled trials regarding lafutidine-based triple therapy of Helicobacter pylori eradication.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0172-6390
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1074-81
|
|
pubmed:meshHeading |
pubmed-meshheading:21410034-Acetamides,
pubmed-meshheading:21410034-Anti-Ulcer Agents,
pubmed-meshheading:21410034-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:21410034-Drug Therapy, Combination,
pubmed-meshheading:21410034-Helicobacter Infections,
pubmed-meshheading:21410034-Helicobacter pylori,
pubmed-meshheading:21410034-Histamine H2 Antagonists,
pubmed-meshheading:21410034-Humans,
pubmed-meshheading:21410034-Piperidines,
pubmed-meshheading:21410034-Pyridines
|
|
pubmed:articleTitle |
Lafutidine-based triple therapy for Helicobacter pylori eradication.
|
|
pubmed:affiliation |
The First Hospital of Lanzhou University, Lanzhou, China.
|
|
pubmed:publicationType |
Journal Article,
Meta-Analysis
|
